How GLP-1 Access Actually Works in Australia

Being approved by the FDA or the MHRA does not make a medicine available in Australia. The Therapeutic Goods Administration (TGA) registers medicines for the Australian market on the Australian Register of Therapeutic Goods (ARTG) independently of any other regulator, so a brand's US or UK status is not evidence of its Australian status. And being TGA-registered does not make a medicine subsidised: PBS listing depends on a separate recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC), and for these medicines the PBS has consistently subsidised the type 2 diabetes indication while treating the obesity indication as a much harder case to fund. Australia also lived through one of the longest documented semaglutide shortages of any market, and in 2024 the government specifically acted to restrict compounded versions of these medicines.

Which of the nine brands are registered in Australia

Seven of the nine brands are registered on the ARTG. Ozempic (semaglutide, Novo Nordisk) has three ARTG entries (308324, 315107, 446290) covering its pen strengths. Rybelsus (oral semaglutide, Novo Nordisk) is registered as three tablet strengths, ARTG 346198, 346199 and 346200, from 7 February 2022. Wegovy (semaglutide 2.4 mg, Novo Nordisk) has a published TGA Australian Public Assessment Report (AusPAR) dated 4 September 2024 and became available in Australia from early August 2024. Mounjaro (tirzepatide, Eli Lilly) has an AusPAR dated 20 September 2024, with at least one confirmed ARTG entry (379333) for the 10 mg pen. Saxenda (liraglutide 6 mg/mL, Novo Nordisk) is registered as ARTG 225804, dating to 24 December 2015. Victoza (liraglutide, Novo Nordisk) has been registered since August 2010. Trulicity (dulaglutide, Eli Lilly) is registered as ARTG 217965, dating to 19 January 2015.

Zepbound does not exist as an Australian brand. Tirzepatide, the molecule sold in the United States as Mounjaro for diabetes and Zepbound for weight management, is sold in Australia under the single brand name Mounjaro for both uses, the same arrangement as the United Kingdom. There is no ARTG entry for a product called Zepbound, and an Australian site or seller using that name for tirzepatide is using a US brand name for a medicine that is not marketed here under it.

Foundayo (orforglipron, Eli Lilly's oral non-peptide GLP-1 medicine) is not TGA-registered as of this page's research in August 2026. Eli Lilly Australia has a submission under active TGA evaluation, but no ARTG entry, AusPAR or confirmed Australian brand name has been published yet. Anyone offering orforglipron for sale in Australia ahead of TGA registration is offering an unregistered medicine.

PBS subsidy is a separate, much narrower gate

TGA registration means a doctor may prescribe a medicine. It does not mean the government subsidises it. For these nine brands, PBS listing has followed a consistent pattern: the type 2 diabetes indication is generally subsidised, the obesity indication generally is not, and the gap between the two is the whole story for an Australian reader trying to work out what they will actually pay.

Ozempic is PBS-listed for type 2 diabetes only, under Authority Required arrangements. Since 1 June 2024, initiation requires telephone or electronic Authority approval, with continuing therapy assessed as Authority Required (Streamlined). To qualify, a patient generally needs to be contraindicated for, or intolerant of, an SGLT2 inhibitor, or to have failed to get an adequate glycaemic response from one, and must be using it in combination with metformin, a sulfonylurea or insulin. Ozempic is not PBS-listed for weight loss, and prescribing it off-label for that purpose is a private, unsubsidised script.

Trulicity is PBS-listed for type 2 diabetes under item 11364D, Authority Required (Streamlined), and is not listed for weight loss. Rybelsus and Victoza are PBS-listed for eligible type 2 diabetes patients under the same class-based restriction framework that applies to semaglutide and liraglutide's diabetes listings; neither is listed for weight management.

Wegovy, Saxenda and Mounjaro, the three brands whose registered use includes chronic weight management, are not currently PBS-subsidised for that indication. Saxenda's sponsor has not submitted it for a PBS obesity listing at all. Wegovy came closest: in November 2025 the PBAC recommended listing semaglutide specifically for people with established cardiovascular disease and obesity, contingent on a price reduction and a risk-sharing arrangement with the sponsor. As of February 2026, arrangements between the sponsor and the Department of Health, Disability and Ageing were still under negotiation, so this is a PBAC recommendation working toward a listing, not a confirmed subsidy. Earlier semaglutide obesity submissions had been rejected by the PBAC on cost-effectiveness grounds. The PBAC has separately flagged Aboriginal and Torres Strait Islander patients with obesity-related comorbidities, people with syndromic or medication-induced obesity, and pre-surgical weight loss as priority populations it wants future company submissions to address, and has said explicitly that it wants any PBS-subsidised GLP-1 access to be a slow, managed rollout rather than opened all at once.

Mounjaro has no PBS listing at all, for either type 2 diabetes or weight management, as of August 2026. Eli Lilly's chief executive said publicly that the company had attempted a PBS listing at least three times and that the sticking point was the PBS's insistence on a cap on the number of eligible patients, with Eli Lilly bearing the cost of anyone above that cap, which he described as an uncapped risk the company would not accept. An estimated 450,000 Australians with type 2 diabetes are affected by the drug's absence from the PBS. Every Mounjaro script in Australia, for any indication, is currently a full private-cost script.

The semaglutide shortage, and what it changed

Australia experienced a severe, multi-year semaglutide shortage that began around April 2022, driven substantially by demand for off-label weight-loss use outweighing the diabetes-indicated supply Novo Nordisk had planned for. By September 2023, TGA guidance stated that semaglutide prescriptions should not be issued without a compelling clinical reason, and that existing patients using it off-label should consider alternative therapies. The shortage continued into 2024: Novo Nordisk advised the TGA that supply would remain limited for the rest of 2024, and the TGA's guidance during that period was that prescribers should not start new patients on Ozempic unless no suitable alternative existed, prioritising continuity of supply for people already using it for type 2 diabetes.

As of February 2026, the TGA has advised that there are no shortages of any GLP-1 receptor agonist medicine in Australia, and that new and existing patients can be prescribed these medicines. This page is not able to confirm a specific shortage history for tirzepatide (Mounjaro) separate from the semaglutide shortage; no formal TGA shortage declaration for Mounjaro specifically was found in this research and none should be assumed.

Compounded semaglutide and tirzepatide are restricted, not an alternative

Australia specifically acted to restrict compounded GLP-1 medicines. On 22 May 2024, the federal Health Minister announced the government would act to protect Australians from what he described as the risks of injecting potentially unsafe and dangerous compounded replicas of weight-loss products, citing more than 20,000 Australians who had already used compounded versions and rising reports of adverse events associated with them. From 1 October 2024, new regulations removed GLP-1 receptor agonists from the pharmacy compounding exemption under the Poisons Standard, meaning Australian compounding pharmacies can no longer legally compound semaglutide-type or tirzepatide-type products.

This is a regulatory restriction, not a grey area and not a cheaper legal alternative to a registered brand. A compounded GLP-1 product obtained in Australia after 1 October 2024 falls outside this restriction and outside the TGA's quality, safety and efficacy evaluation that every ARTG-registered brand on this page has been through.

Private cost

Neither the TGA nor the Department of Health publishes a private retail price for these medicines, because that price is set commercially by individual pharmacies, not fixed the way a PBS-subsidised item's patient co-payment is. This page does not quote a monthly cost figure for the unsubsidised brands (Wegovy, Saxenda, Mounjaro) or for off-label private use of the PBS-diabetes-listed brands, because the figures found in this research came from pharmacy and telehealth marketing pages rather than a primary or reputable news source, and are not stable enough to publish as an established number. Anyone comparing private options in Australia should treat an advertised headline price as a starting point rather than a total: consultation, follow-up and dispensing fees are commonly charged separately from the medicine itself.

The evidence, one row per claim

Questions people ask

Sources

1. TGA, Australian Register of Therapeutic Goods
2. TGA ARTG entry 308324, Ozempic
3. TGA ARTG entry 346198, Rybelsus
4. TGA AusPAR, Wegovy
5. TGA ARTG entry 379333, Mounjaro
6. TGA ARTG entry 225804, Saxenda
7. PBS Schedule, item 11364D, Trulicity
8. TGA, prescription medicines under evaluation
9. PBS, restriction changes to type 2 diabetes mellitus medicines
10. PBS, PBAC advice on equitable access to GLP-1 obesity treatments
11. ABC News, PBS failure to list Mounjaro for type 2 diabetics questioned
12. Law Society Journal (LSJ), weight-loss drugs and the regulatory environment